Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. ORGO
stocks logo

ORGO

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
172.65M
+36.31%
0.210
+425%
99.70M
+15%
-0.090
-47.06%
115.90M
+14.75%
-0.010
-90%
Estimates Revision
The market is revising Upward the revenue expectations for Organogenesis Holdings Inc. (ORGO) for FY2025, with the revenue forecasts being adjusted by 5.37% over the past three months. During the same period, the stock price has changed by -1.60%.
Revenue Estimates for FY2025
Revise Upward
up Image
+5.37%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-333.33%
In Past 3 Month
Stock Price
Go Down
down Image
-1.60%
In Past 3 Month
Wall Street analysts forecast ORGO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ORGO is 9.00 USD with a low forecast of 9.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast ORGO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ORGO is 9.00 USD with a low forecast of 9.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 4.920
sliders
Low
9.00
Averages
9.00
High
9.00
Current: 4.920
sliders
Low
9.00
Averages
9.00
High
9.00
BTIG
Buy
maintain
$7 -> $9
2025-11-20
Reason
BTIG
Price Target
$7 -> $9
2025-11-20
maintain
Buy
Reason
BTIG raised the firm's price target on Organogenesis to $9 from $7 and keeps a Buy rating on the shares. With the changes in reimbursement set to take effect in 2026, there will be clear share winners and share losers, and the firm believes that Organogenesis will be one of those that may be a share winner based on its current product pricing structure relative to the finalized pricing structure at $127.28 per cm, the analyst tells investors in a research note.
Morgan Stanley
Drew Ranieri
Hold
Maintains
$4 → $6
2025-03-05
Reason
Morgan Stanley
Drew Ranieri
Price Target
$4 → $6
2025-03-05
Maintains
Hold
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Organogenesis Holdings Inc (ORGO.O) is 23.76, compared to its 5-year average forward P/E of 35.82. For a more detailed relative valuation and DCF analysis to assess Organogenesis Holdings Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
35.82
Current PE
23.76
Overvalued PE
121.75
Undervalued PE
-50.11

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
14.30
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
21.28
Undervalued EV/EBITDA
7.33

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
1.66
Current PS
0.00
Overvalued PS
3.00
Undervalued PS
0.32
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areSelling! The selling amount has increased 1870.37% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areSelling! The selling amount has increased 1870.37% over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

ORGO News & Events

Events Timeline

(ET)
2025-09-25
16:53:57
Organogenesis shares progress on its second Phase 3 ReNu trial
select
2025-07-15 (ET)
2025-07-15
09:34:04
Video: Why Organogenesis And MiMedx Are Sinking Today
select
link
2025-07-15
09:10:00
Organogenesis 'pleased' with CMS proposal on skin substitute
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.5
11-08NASDAQ.COM
Organogenesis Shares Jump 54% Following Strong Q3 Revenue and Upgraded Forecast

  • Strong Q3 Performance: Organogenesis Holdings Inc. reported a 53.72% increase in stock price after posting $150.5 million in net product revenue for Q3 2025, a 31% year-over-year growth, with significant contributions from Advanced Wound Care and Surgical & Sports Medicine.

  • Improved Financial Metrics: The company achieved a net income of $21.6 million ($0.11 per share) and an adjusted EBITDA of $30.1 million, both showing substantial increases compared to the previous year.

  • Revised Full-Year Guidance: For the full year 2025, Organogenesis raised its revenue guidance to $500 million-$525 million, anticipating 4-9% growth, and adjusted EBITDA expectations of $45.5 million-$68.3 million.

  • Market Reaction: Following the earnings announcement, ORGO's trading volume surged, reflecting positive market sentiment, with the stock's 52-week range noted between approximately $2.61 and $6.71.

[object Object]
Preview
9.5
11-07NASDAQ.COM
After-Hours Surge in GMED, TNDM, ICUI, ORGO, SKIN, TXG Fueled by Q3 Results

  • Globus Medical Earnings Surge: Globus Medical's stock rose 24.37% after reporting a Q3 net income of $119 million and raising its 2025 revenue outlook to $2.86-$2.90 billion, with non-GAAP EPS guidance increased to $3.75-$3.85.

  • Tandem Diabetes Care Recovery: Tandem Diabetes Care's stock rebounded 20.03% after narrowing its Q3 net loss to $21.2 million and reaffirming its 2025 sales guidance of approximately $1 billion.

  • Organogenesis Holdings Growth: Organogenesis Holdings saw a 19.28% increase in stock price following a Q3 net income of $21.6 million and an updated 2025 revenue forecast of $500-$525 million.

  • ICU Medical and 10x Genomics Updates: ICU Medical's stock rose 14.14% after narrowing its Q3 net loss, while 10x Genomics advanced 8.92% despite a Q3 net loss, with both companies revising their 2025 guidance.

[object Object]
Preview
8.0
11-04Newsfilter
Organogenesis Commends CMS for Major Advancement in Payment Reform

  • CMS Payment Reform: Organogenesis Holdings Inc. commends the Centers for Medicare & Medicaid Services (CMS) for implementing a new payment methodology for skin substitutes and cellular tissue-based products under the CY 2026 Physician Fee Schedule, which aims to enhance access and address current system abuses.

  • Clinical Differentiation Recognition: The company expresses satisfaction that CMS has acknowledged the clinical differences of PMA products, leading to higher payments and broader access, while emphasizing their commitment to collaborate with CMS and stakeholders for further advancements in regenerative medicine.

  • Market Positioning: With over forty years in regenerative medicine, Organogenesis believes it is well-positioned in the skin substitutes market for 2026 and beyond, supported by a diverse, evidence-based portfolio across various FDA categories.

  • Forward-Looking Statements: The release includes forward-looking statements regarding expectations for CMS's new payment structure and its potential impact on access to PMA products, while cautioning that actual results may differ due to various risks and uncertainties.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Organogenesis Holdings Inc (ORGO) stock price today?

The current price of ORGO is 4.92 USD — it has decreased -1.4 % in the last trading day.

arrow icon

What is Organogenesis Holdings Inc (ORGO)'s business?

Organogenesis Holdings Inc. is a regenerative medicine company focused on the development, manufacture and commercialization of solutions for the advanced wound care and surgical and sports medicine markets. It offers a portfolio of regenerative products to address patient needs across the continuum of care. Its wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for the treatment of DFUs; PuraPly AM as an antimicrobial barrier, cross-linked with extracellular matrix scaffold for a variety of wound types; and Affinity, Novachor and NuShield placental allografts to address a variety of wound sizes and types as a protective barrier and extracellular matrix scaffold. Its sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM and PuraPly SX for the management of open wounds in a surgical setting.

arrow icon

What is the price predicton of ORGO Stock?

Wall Street analysts forecast ORGO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ORGO is 9.00 USD with a low forecast of 9.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Organogenesis Holdings Inc (ORGO)'s revenue for the last quarter?

Organogenesis Holdings Inc revenue for the last quarter amounts to 150.86M USD, increased 30.98 % YoY.

arrow icon

What is Organogenesis Holdings Inc (ORGO)'s earnings per share (EPS) for the last quarter?

Organogenesis Holdings Inc. EPS for the last quarter amounts to 0.11 USD, increased 22.22 % YoY.

arrow icon

What changes have occurred in the market's expectations for Organogenesis Holdings Inc (ORGO)'s fundamentals?

The market is revising Upward the revenue expectations for Organogenesis Holdings Inc. (ORGO) for FY2025, with the revenue forecasts being adjusted by 5.37% over the past three months. During the same period, the stock price has changed by -1.60%.
arrow icon

How many employees does Organogenesis Holdings Inc (ORGO). have?

Organogenesis Holdings Inc (ORGO) has 869 emplpoyees as of December 05 2025.

arrow icon

What is Organogenesis Holdings Inc (ORGO) market cap?

Today ORGO has the market capitalization of 624.41M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free